Numerous tumor‐specific genetic alterations such as typical isocitrate dehydrogenase (IDH) mutation and chromosome 1p/19q codeletion were routinely applied in diagnosis according to the 2021 World Health Organization (WHO) classification system, but whether these gene aberrations affect glioma progression remains debatable.3, 4. Here, IDH1 is linked to central nervous system cancer.